Emerging therapies for fibromyalgia: an update (Q37756999)

22 August 2017

1 reference

title

Emerging therapies for fibromyalgia: an update (English)

1 reference

22 August 2017

0 references

2

Dan Buskila

1 reference

22 August 2017

Jacob N Ablin

1

0 references

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Emerging Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

15

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

521-533

1 reference

Psychophysical and EEG responses to repeated experimental muscle pain in humans: pain intensity encodes EEG activity

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Group differences in pain modulation: pain-free women compared to pain-free men and to women with TMD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Central sensitization in tension-type headache--possible pathophysiological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Chronic widespread pain in the population: a seven year follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Pathogenesis of fibromyalgia - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Chronic widespread pain and fibromyalgia: what we know, and what we need to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The prevalence and characteristics of fibromyalgia in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Patients' experiences of living with and receiving treatment for fibromyalgia syndrome: a qualitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Societal and patient burden of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Epidemiology, costs, and the economic burden of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Central sensitization in fibromyalgia and other musculoskeletal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Neurophysiologic evidence for a central sensitization in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Treatment of fibrositis with fluoxetine hydrochloride (Prozac).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

A double-blind placebo controlled trial of fluoxetine in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Duloxetine and other antidepressants in the treatment of patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Sleep quality and pain threshold in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Fibromyalgia: the role of sleep in affect and in negative event reactivity and recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Sleep in fibromyalgia patients: subjective and objective findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Sleep and circadian rhythm disorders in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Musculosketal Symptoms and Non-REM Sleep Disturbance in Patients with “Fibrositis Syndrome” and Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The significance of the sleeping-waking brain for the understanding of widespread musculoskeletal pain and fatigue in fibromyalgia syndrome and allied syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Sleep apnea in male patients with the fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Sleep continuity and architecture: associations with pain-inhibitory processes in patients with temporomandibular joint disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Eszopiclone for the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The effect of melatonin in patients with fibromyalgia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Fibromyalgia--a syndrome associated with decreased nocturnal melatonin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Potential use of melatonergic drugs in analgesia: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Ramelteon: a review of its therapeutic potential in sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Focus on topiramate in neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Topiramate as a treatment for pain in multisomatoform disorder patients: an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Effectiveness of levetiracetam in the treatment of lumbar radiculopathy: an open-label prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Levetiracetam in spinal cord injury pain: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Effect of levetiracetam on the postmastectomy pain syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Successful use of zonisamide for central poststroke pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Fibromyalgia patients show an abnormal dopamine response to pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Rotigotine transdermal delivery for the treatment of restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

EULAR evidence-based recommendations for the management of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Cannabinoids in the management of difficult to treat pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Nabilone for the treatment of pain in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Neuronal plasticity: increasing the gain in pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Decreased central mu-opioid receptor availability in fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Modafinil for excessive sleepiness associated with shift-work sleep disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Modafinil in fibromyalgia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

An open-label study of quetiapine in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

New developments in the diagnosis of fibromyalgia syndrome: say goodbye to tender points?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

The Selective GABA Reuptake Inhibitor Tiagabine for the Treatment of Generalized Anxiety Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.491509

10.1517/14728214.2010.491509

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference